

Study Title: Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION

Study Protocol Date / Version: 23 July 2018/Version 2.0

COMPOSITION OF STUDY STEERING COMMITTEE

External Members:

| Role | Member | Country | Main expertise |
|------------------------|--------------------|-----------|------------------------------|
| Chairperson/ Moderator | Helmut Butzkueven | Australia | Neurology |
| Members | Joseph Berger | USA | Neurology/Infectious disease |
| | Maria Trojano | Italy | Neurology |
| | Nicholas Moore | France | Pharmacoepidemiology |
| | Tjalf Ziemssen | Germany | Clinical Neuroscience |
| | Philip Schein | USA | Oncology |
| | Sandra Vukusic | France | Neurology |
| | Christoph Thalheim | Belgium | Patients' representative |
| | Jan Hillert | Sweden | Neurology |
| | Melinda Magyari | Denmark | Neurology |

Merck Members:

| Role | Name |
|--|--------------------------|
| Associate Director, Global Epidemiology | Meritxell Sabidó |
| Senior Clinical Research Manager, Regional Clinical Operations | Cristina Pinuaga Astorga |
| Associate Director, Global Biostatistics | Aida Aydemir |
| Medical Director, Global Patient Safety | Tanuja Halady |